Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial

At the beginning of the SARS-CoV-2 pandemic, developing of new treatments to control the spread of infection and decrease morbidity and mortality are necessary. This prospective, open-label, case-control intervention study evaluates the impact of the oral intake of the probiotic yeast Kluyveromyces...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarro-López, Vicente, Hernández-Belmonte, Adriana, Pérez Soto, Maria Isabel, Ayo-González, Maikel, Losa-Rodríguez, Guillermo, Ros-Sánchez, Esther, Martínez-Gabarrón, Maravillas, Sánchez-Pellicer, Pedro, Aguera-Santos, Juan, Núñez-Delegido, Eva, Ruzafa-Costas, Beatriz, Picó-Monllor, José Antonio, Navarro-Moratalla, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398813/
https://www.ncbi.nlm.nih.gov/pubmed/36035620
http://dx.doi.org/10.1016/j.medmic.2022.100061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398813/
https://www.ncbi.nlm.nih.gov/pubmed/36035620
http://dx.doi.org/10.1016/j.medmic.2022.100061

Ejemplares similares